IL-13 INHIBITION USED FOR ATOPIC DISEASES IS ASSOCIATED WITH RISK OF PSORIATIC ARTHRITIS
Abstract: POS1604
Authors: Zhao S.S. et al.
Key content:
Musculoskeletal adverse events that resemble enthesitis and psoriatic arthritis have been reported after initiation of dupilumab therapy. Dupilumab reduces eosinophil counts in clinical trials that is considered a correlate of IL13 inhibition. A missense variant of the IL13 gene (rs20541) was identified that was associated with lower circulating eosinophil counts in a study of 563946 individuals. Genetic analyses were then performed based on studies of PsA, psoriasis, axSpa, iritis, Crohn`s disease and ulcerative colitis. The genetically proxied IL13i variant was associated with an increased risk of PsA (OR 37.39, 95%CI 11.52, 121.34), psoriasis (OR 20.08, 95%CI 4.38, 92.01) and Crohn`s disease (OR 3.49, 95%CI 1.38, 8.81).
Relevance:
An association of genetically proxied IL-13 inhibition with an increased risk for psoriasis, PsA and Crohn´s disease was elegantly shown in this study. This may likely represent a class effect of IL4/IL13 inhibition such as dupilumab and tralokinumab that might induce IL17 activation. In daily practice, clinicians should be aware of the increased risk of these diseases in the context of therapies like dupilumab and tralokinumab.
